FDA Approval: Taletrectinib and ROS1 NSCLC

Podcast | English | 2025 | 29 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer to help place this new agent in the proper perspective.

Podcast Hosts:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Enriqueta Felip, MD, PhD, Director Thoracic Oncology Unit, Vall d'Hebron Institute of Oncology, Section in Chief, Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
Jorge Neiva, MD, Associate Professor of Clinical Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA